Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

BACKGROUND: The integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating t...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Andrew N, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel, Wensing, Annemarie, Lundgren, Jens D, De Luca, Andrea, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Bansi-Matharu, Loveleen, Nakagawa, Fumiyo, Kalua, Thokozani, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Clayden, Polly, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Bertagnolio, Silvia, Calmy, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361866/
https://www.ncbi.nlm.nih.gov/pubmed/30503325
http://dx.doi.org/10.1016/S2352-3018(18)30317-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361866/
https://www.ncbi.nlm.nih.gov/pubmed/30503325
http://dx.doi.org/10.1016/S2352-3018(18)30317-5

Ejemplares similares